Audit: QRS - Beta-Carotene for Health & Longevity

Audit conducted on 07/09/2026 02:12 using AI4L / Opus 5

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, tier lists, gate items, markers and cadence trace to ER `Therapeutic Protocol`, `Expected Benefits`, `Potential Risks & Side Effects`, `Key Interactions & Contraindications`, `Practical Considerations` and `Monitoring Protocol & Defining Success`.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s “⚠️ Conflicted” markers carried through as “(conflicted)” on benefits_low and risks_low; marker_5 keeps “No established target”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication strength preserved (alcohol appears as a stop item, matching the ER’s “Absolute contraindication at heavy intake”).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates drawn only from `Key Interactions & Contraindications`; tiers only from the two tiered ER sections; no modifying-factor content migrated.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, expert names, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, harm-forward framing mirrors the ER’s own “unusually strong on harm and unusually weak on benefit” stance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified thresholds (4.0 mg/L, 3,000 µg RAE, 30 g ethanol) alongside plain-language benefit statements.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are declarative (“Absorption saturates above roughly 20–30 mg per dose”), not instructional.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; protocol cells state practice, not orders.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of recommend/advise/should in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms (Child-Pugh, erythropoietic protoporphyria, carotenodermia) are the ER’s own biomarker and condition names, not avoidable jargon.
2.8	Information is presented in a concise and very compact manner	🟢	One line per benefit/risk tier; protocol subs held to one or two short sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the source.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Serum cotinine, RBP and lutein/zeaxanthin tracking assume a proactive self-testing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Eight-marker monitoring panel and monthly daylight skin checks presuppose that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content depth (biomarker targets, isomer-independent dose ceilings) is well past general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The smoking/asbestos sign reversal is surfaced in At-A-Glance, Contraindications, Risks and the cotinine marker.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“capsule”, “softgel”-free phrasing and “supplementation” follow the ER’s register; no colloquialisms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings byte-identical to [qrs_template].
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; the repeatable `marker_#_*` and `qualitative_item_#` rows expanded to marker_1–8 and qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	`website="evidence_review"`, `website="audit"`, `website="full_review"`, the full stylesheet, override link and footer disclaimer are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped by this QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard preventive intake”, “Best time of day”, “Single versus split dosing”) and interaction labels reproduce the ER’s bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Skin photoprotection”, “Macular benefit”, “Cognitive signal”) are the ER’s own terms from the `Time to effect` bullet; marker names match the ER biomarker table.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; tiers rendered via `<strong>` labels and CSS card colors.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each ER tier collapsed to a single semicolon-separated line; protocol reduced from twelve ER bullets to three cells; no second page structure added.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening `---` on line 3, closing `---` on line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only `duration: "00:03"` is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: `er_filename: beta_carotene_2026-0907-0002_Opus_ER.md`.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: `qrs_prompt_version: 26.7.02`, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: `qrs_creation_date: 2026-0907-0201`.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: `qrs_creator_ai_nickname: Opus`.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: `qrs_creator_ai_fullname: Opus 5`.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; consistent with 5.4.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	“Beta-Carotene for Health & Longevity - Quick Reference Sheet” (line 22), with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	Line 417: “Beta-Carotene for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0907-0201 → “09/07/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block is structurally identical to the template; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Compresses all four Conclusion paragraphs: food-versus-capsule split, the three real uses, and the smoker/asbestos harm.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a Conclusion sentence (“turns, partly and very unevenly, into vitamin A”; “As food, it travels with a diet that tracks longer life”; “makes skin harder to burn”; “relieves a rare inherited sunlight intolerance”; “without the risk of overload”; “raise lung cancer and heart death”).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “sunlight intolerance”, “harder to burn” and “heart death” replace the clinical terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All six items trace to that section’s “Populations who should avoid Beta-Carotene” list and its Alcohol bullet.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-population bullets represented; the combined alcohol/liver bullet is split into two items.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six `<li>` elements inside the `stop_items` span (lines 577–584).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes introduce trailing clauses; the ER’s explanatory glosses (“precancerous airway lining changes”, “about three standard drinks”) were dropped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The 10–15 year quit window, the 30 g ethanol threshold, Child-Pugh Class B or C, and the 3,000 µg RAE ceiling are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five avoid-populations plus an absolute alcohol contraindication, and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All seven items map one-to-one onto that section’s interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets carried; Alcohol correctly omitted because it sits in Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven `<li>` elements inside the `caution_items` span (lines 592–607).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a label plus a three-to-six-word consequence; the ER’s mitigation sentences and the Elinder and Raeini-Sarjaz citations were stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained for both bullets that carry them: “(cholestyramine, colestipol, colesevelam)” and “(retinol, retinyl palmitate, cod liver oil, isotretinoin)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	All three cells derive from ER `Therapeutic Protocol` bullets, including the 3–6 mg practice ceiling, the 3–5 g fat rule and the 20–30 mg saturation point.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose, timing and dosing frequency — the three decisions a reader must make before taking the compound.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER `Therapeutic Protocol` section contains twelve actionable bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All nine spans populated; no placeholder or empty-state text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Exactly the three latencies named in the ER’s `Practical Considerations` “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Skin photoprotection (High tier) first, then macular benefit and cognitive signal (both Medium, in ER order).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; “At least 10 weeks”, “About six years” and “Roughly 18 years” all traceable to the ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All twelve items are the ER’s own benefit sub-headings, lower-cased and joined by semicolons.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	No Magnitude figures, confidence intervals, p-values or study names carried; the only retained qualifier is the ER’s own “Conflicted” evidence marker, which 1.2/1.3 require.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s explanatory parentheticals (e.g., “progressive damage to the central retina”, “inherited progressive retinal degeneration”) are stripped; only the ER’s own conflict marker remains, rendered as “(conflicted)” because 4.4 forbids the ⚠️ emoji.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	All eight items are the ER’s own risk sub-headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	No relative risks, confidence intervals or trial references carried; only the ER’s “Conflicted” marker on all-cause mortality is retained.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER parentheticals stripped; the “(conflicted)” marker on all-cause mortality is the ER’s own evidence-status flag, whose removal would strengthen the claim contrary to 1.3.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Names, targets and rationales reproduce the ER `Monitoring Protocol & Defining Success` biomarker table.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All eight ER rows present and in ER order: serum beta-carotene, serum retinol, retinol-binding protein, total plasma carotenoids, plasma lutein and zeaxanthin, fasting lipid panel, ALT, serum cotinine.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Baseline, three-month and annual repeats plus the alcohol-conditional liver recheck, condensed from the ER’s cadence paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Taken from the ER’s “Qualitative markers worth tracking alongside the labs” list.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All five ER qualitative markers present, in ER order and near-verbatim wording.

Issues 07/09/2026 02:12

Pass rate 100.00%. No issues found.

Issues 07/09/2026 02:06

14.3 — Cadence text sourced outside Monitoring: The [monitoring_cadence] span at line 768 ends with “Six weeks pass after stopping before a repeat carotenoid measurement is interpretable”, which is drawn from the ER Discontinuation & Cycling section (ER line 380) rather than the ER Monitoring section that item 14.3 requires.

Fixes 07/09/2026 02:06

14.3 — Cadence text sourced outside Monitoring: Removed the closing sentence “Six weeks pass after stopping before a repeat carotenoid measurement is interpretable” from [monitoring_cadence], leaving only the baseline / three-month / annual cadence drawn from the ER Monitoring section.